Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT03207815) enrolled 74 people with active non-infectious uveitis (inflammation inside the eye not caused by infection) — 38 received filgotinib, an investigational oral medicine, and 36 received a placebo (a dummy pill with no active ingredient). The trial ran for up to 52 weeks and was primarily measuring how many participants in each group experienced what the researchers called "treatment failure" by week 24 — meaning their eye inflammation got worse or did not improve enough according to set criteria, such as new areas of inflammation appearing, inflammation scores not coming down to target levels, or vision worsening by a meaningful amount. The reported data shows that by week 24, 37.5% of participants in the filgotinib group met the criteria for treatment failure, compared with 67.6% in the placebo group. For the secondary measure of how quickly treatment failure occurred (from week 6 onward), the reported data shows a median time of 22.0 weeks in the placebo group; a median figure was not reported for the filgotinib group, which in this context means treatment failure did not occur in at least half of that group during the study period. For the remaining secondary measures — changes in eye inflammation scores (vitreous haze and anterior chamber cell grades), vision scores, and retinal thickness — small numerical changes were reported in both groups at week 52, but the data as submitted does not include the additional detail needed to describe meaningful differences between the groups for those measures. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 39023880) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Uveitis Trial, Terminated
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with a specific type of eye inflammation (uveitis) that is not caused by an infection, affecting the middle, back, or entire part of the eye
- Your eye inflammation is still active at your first visit, meaning it has not fully responded after at least 2 weeks of taking a moderate dose of steroid tablets (such as prednisone)
- You show at least one sign of ongoing inflammation in one eye, such as active lesions in the eye, or a certain level of inflammation detected during an eye exam (confirm with trial site for exact measurements)
- You do not have active tuberculosis (TB), and any past or latent TB has already been treated
Who may not be able to join:
- You have high pressure inside your eye and/or severe glaucoma
- Your uveitis is caused or suspected to be caused by an infection, such as TB, cytomegalovirus, herpes, Lyme disease, toxoplasmosis, or several other infectious conditions
Important: Always verify eligibility with the trial site directly before applying.
Please note: There may be additional eligibility requirements beyond those listed here. The trial team will review your full medical history to determine whether this trial is right for you. This information is for general understanding only and is not medical advice.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Gilead Study Director, Gilead Sciences
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percentage of Participants Failing Treatment for Active NonInfectious Uveitis by Week 24
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.